/VICO.ST

VICO.ST Stock - Vicore Pharma Holding AB (publ)

Q: What is the analyst price target for VICO.ST?

Analyst price target information is not currently available for VICO.ST.

Q: What is VICO.ST's market cap?

Market capitalization information is not currently available for VICO.ST.

Healthcare|Biotechnology|STO

$11.08+5.52%

+$0.58 (+5.52%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $12.19

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VICO.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.41

52W High$14.10

52W Low$6.09

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$109.35M	N/A	N/A	N/A	N/A
Gross Profit	$109.35M	$-3,421,000	$-3,612,000	$-3,598,000	$-3,537,000
Gross Margin	100.0%	N/A	N/A	N/A	N/A
Operating Income	$-194,189,000	$-321,506,000	$-290,725,000	$-294,818,000	$-149,538,000
Net Income	$-168,634,000	$-310,942,000	$-288,422,000	$-296,481,000	$-146,862,000
Net Margin	-154.2%	N/A	N/A	N/A	N/A
EPS	$-0.75	$-3.22	$-3.99	$-4.25	$-2.71

Company Overview

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.

Visit Website

Earnings History & Surprises

VICO.ST

Beat Rate

40%

Last 15 quarters

Avg Surprise

+0.4%

EPS vs Estimate

Beats / Misses

6/9

Last 12 quarters

Latest EPS

$-0.48

Q4 2025

EPS Surprise History

Q1 24

-69.5%

$-1.00vs$-0.59

Q2 24

No data

Q3 24

No data

Q4 24

No data

Q1 25

-11.1%

$-0.40vs$-0.36

Q2 25

-3.5%

$-0.48vs$-0.46

Q3 25

-6.8%

$-0.49vs$-0.46

Q4 25

-4.3%

$-0.48vs$-0.46

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 27, 2026	—	—	—	—
Q4 2025	Nov 5, 2025	$-0.46	$-0.48	-4.3%	✗ MISS
Q3 2025	Aug 22, 2025	$-0.46	$-0.49	-6.8%	✗ MISS
Q2 2025	May 6, 2025	$-0.46	$-0.48	-3.5%	✗ MISS
Q1 2025	Feb 27, 2025	$-0.36	$-0.40	-11.1%	✗ MISS
Q4 2024	Nov 5, 2024	—	$-0.54	—	—
Q3 2024	Aug 22, 2024	—	$-0.50	—	—
Q2 2024	May 3, 2024	—	$0.28	—	—
Q1 2024	Feb 28, 2024	$-0.59	$-1.00	-69.5%	✗ MISS
Q4 2023	Nov 2, 2023	$-0.65	$-0.58	+10.8%	✓ BEAT
Q3 2023	Aug 24, 2023	$-0.73	$-0.85	-16.4%	✗ MISS
Q2 2023	May 4, 2023	$-0.78	$-0.81	-3.8%	✗ MISS
Q1 2023	Mar 1, 2023	$-0.82	$-0.83	-1.1%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.97	$-0.95	+2.0%	✓ BEAT
Q3 2022	Aug 25, 2022	$-1.20	$-0.92	+23.5%	✓ BEAT
Q2 2022	May 5, 2022	$-1.22	$-1.30	-6.7%	✗ MISS
Q1 2022	Feb 25, 2022	$-1.51	$-1.12	+25.8%	✓ BEAT
Q4 2021	Nov 4, 2021	$-1.77	$-1.36	+23.2%	✓ BEAT
Q3 2021	Aug 26, 2021	$-1.76	$-0.98	+44.3%	✓ BEAT

Frequently Asked Questions about VICO.ST

What is VICO.ST's current stock price?

Vicore Pharma Holding AB (publ) (VICO.ST) is currently trading at $11.08 per share. The stock has moved +5.52% today.

What is the analyst price target for VICO.ST?

No analyst price targets are currently available for this stock.

What sector is Vicore Pharma Holding AB (publ) in?

Vicore Pharma Holding AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.

What is VICO.ST's market cap?

Vicore Pharma Holding AB (publ) has a market capitalization of $2.60 billion, making it a mid-cap company.

Does VICO.ST pay dividends?

No, Vicore Pharma Holding AB (publ) does not currently pay a dividend to shareholders.